Five years of self-administered hyaluronidase facilitated subcutaneous immunoglobulin (fSCIg) home therapy in a patient with primary immunodeficiency

Journal of Clinical Pathology

Volumn 69, Issue 1, 2016, Pages 87-88

  Carne, Emily ^a   Ponsford, Mark ^a   El Shanawany, Tariq ^a   Williams, Paul ^a   Pickersgill, Trevor ^a   Jolles, Stephen ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONOGLUCOSAMINIDASE; IMMUNOGLOBULIN;

ADULT; CASE REPORT; DRUG ADMINISTRATION; DRUG SELF ADMINISTRATION; FEMALE; HUMAN; IMMUNOLOGY; SEVERE COMBINED IMMUNODEFICIENCY; SUBCUTANEOUS DRUG ADMINISTRATION; THIGH; TIME FACTOR; TREATMENT OUTCOME;

ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYALURONOGLUCOSAMINIDASE; IMMUNOGLOBULINS; INFUSIONS, SUBCUTANEOUS; SELF ADMINISTRATION; SEVERE COMBINED IMMUNODEFICIENCY; THIGH; TIME FACTORS; TREATMENT OUTCOME;

EID: 84953364779     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2015-202901     Document Type: Letter

References (8)

1. Bruton OC. Agammaglobulinemia. Pediatrics 1952;9:722-8.
2. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: Advantages of the subcutaneous route. BioDrugs 2007;21:105-16.
3. Wasserman RL, Melamed I, Stein MR, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 2012;130:951-7.e11.
4. Jolles S. Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency. Immuno Targets Therapy 2013;2013:2:125-33.
5. Bruton OC. A decade with agammaglobulinemia. J Pediatr 1962;60:672-6.
6. Knight E, Carne E, Novak B, et al. Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin home therapy in a patient with primary immunodeficiency. J Clin Pathol 2010;63:846-7.
7. Jolles S. The variable in common variable immunodeficiency: A disease of complex phenotypes. J Allergy Clin Immunol Pract 2013;1:545-56.
8. Frost GI. Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007;4:427-40.